Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,336 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discovery of a novel series of GPR119 agonists: Design, synthesis, and biological evaluation of N-(Piperidin-4-yl)-N-(trifluoromethyl)pyrimidin-4-amine derivatives.
Kubo O, Takami K, Kamaura M, Watanabe K, Miyashita H, Abe S, Matsuda K, Tsujihata Y, Odani T, Iwasaki S, Kitazaki T, Murata T, Sato K. Kubo O, et al. Among authors: iwasaki s. Bioorg Med Chem. 2021 Jul 1;41:116208. doi: 10.1016/j.bmc.2021.116208. Epub 2021 May 9. Bioorg Med Chem. 2021. PMID: 34010766 Free article.
Discovery of novel somatostatin receptor subtype 5 (SSTR5) antagonists: Pharmacological studies and design to improve pharmacokinetic profiles and human Ether-a-go-go-related gene (hERG) inhibition.
Yamasaki T, Hirose H, Yamashita T, Takakura N, Morimoto S, Nakahata T, Kina A, Nakano Y, Okano Tamura Y, Sugama J, Odani T, Shimizu Y, Iwasaki S, Watanabe M, Maekawa T, Kasai S. Yamasaki T, et al. Among authors: iwasaki s. Bioorg Med Chem. 2017 Aug 1;25(15):4153-4162. doi: 10.1016/j.bmc.2017.06.003. Epub 2017 Jun 13. Bioorg Med Chem. 2017. PMID: 28622905
Discovery of novel 5-oxa-2,6-diazaspiro[3.4]oct-6-ene derivatives as potent, selective, and orally available somatostatin receptor subtype 5 (SSTR5) antagonists for treatment of type 2 diabetes mellitus.
Hirose H, Yamasaki T, Ogino M, Mizojiri R, Tamura-Okano Y, Yashiro H, Muraki Y, Nakano Y, Sugama J, Hata A, Iwasaki S, Watanabe M, Maekawa T, Kasai S. Hirose H, et al. Among authors: iwasaki s. Bioorg Med Chem. 2017 Aug 1;25(15):4175-4193. doi: 10.1016/j.bmc.2017.06.007. Epub 2017 Jun 9. Bioorg Med Chem. 2017. PMID: 28642028
Discovery of a novel series of indolinylpyrimidine-based GPR119 agonists: Elimination of ether-a-go-go-related gene liability using a hydrogen bond acceptor-focused approach.
Kamaura M, Kubo O, Sugimoto H, Noguchi N, Miyashita H, Abe S, Matsuda K, Tsujihata Y, Odani T, Iwasaki S, Murata T, Sato K. Kamaura M, et al. Among authors: iwasaki s. Bioorg Med Chem. 2021 Mar 15;34:116034. doi: 10.1016/j.bmc.2021.116034. Epub 2021 Jan 23. Bioorg Med Chem. 2021. PMID: 33548803 Free article.
Design, Synthesis, and Evaluation of (2-Aminocyclopropyl)phenyl Derivatives as Novel Positron Emission Tomography Imaging Agents for Lysine-Specific Demethylase 1 in the Brain.
Hattori Y, Matsuda S, Baba R, Matsumiya K, Iwasaki S, Constantinescu CC, Morley TJ, Carroll VM, Papin C, Gouasmat A, Alagille D, Tamagnan G, Koike T. Hattori Y, et al. Among authors: iwasaki s. J Med Chem. 2021 Apr 8;64(7):3780-3793. doi: 10.1021/acs.jmedchem.0c01937. Epub 2021 Mar 17. J Med Chem. 2021. PMID: 33729758
Design, synthesis, and structure-activity relationship of TAK-418 and its derivatives as a novel series of LSD1 inhibitors with lowered risk of hematological side effects.
Hattori Y, Matsumoto S, Morimoto S, Daini M, Toyofuku M, Matsuda S, Baba R, Murakami K, Iwatani M, Oki H, Iwasaki S, Matsumiya K, Tominari Y, Kimura H, Ito M. Hattori Y, et al. Among authors: iwasaki s. Eur J Med Chem. 2022 Sep 5;239:114522. doi: 10.1016/j.ejmech.2022.114522. Epub 2022 Jun 7. Eur J Med Chem. 2022. PMID: 35749987 Free article.
1,336 results